|Bid||50.10 x 900|
|Ask||65.00 x 1300|
|Day's Range||55.02 - 57.54|
|52 Week Range||37.44 - 90.98|
|Beta (3Y Monthly)||2.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||74.56|
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
Ultragenyx Pharmaceutical will pay $20 million to partner with — and potentially acquire — biotech startup GeneTx as it studies a treatment for a rare disease called Angelman syndrome.
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, and GeneTx Biotherapeutics LLC, today announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, a serious, debilitating, rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide. GTX-102 is currently in late preclinical development with an investigational new drug (IND) application expected to be filed with the U.S. Food and Drug Administration (FDA) in the first half of 2020.
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Tom Kassberg, the company’s Chief Business Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 1:20 PM ET in New York, NY. The live and archived webcast of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases.
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.94% and 11.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Strong Crysvita® (burosumab) Launch Continues with Approximately 960 Patients on Reimbursed Commercial Therapy in the United States Ultragenyx Submits New Drug Application to.
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for UX007 (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), a group of genetic disorders in which the body is unable to convert long-chain fatty acids into energy. The FDA previously granted Rare Pediatric Disease Designation and Fast Track designation, which enables eligibility for Priority Review, if relevant criteria are met.
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ultragenyx...
NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics$30.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RAREView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding RARE are favorable, with net inflows of $2.42 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has promoted Erik Harris to Executive Vice President and Chief Commercial Officer, effective June 11, 2019. Mr. Harris joined Ultragenyx in 2017 as Senior Vice President, Head of North American Commercial Operations, leading the launches of Crysvita® (burosumab) and Mepsevii® (vestronidase alfa).
Emil Kakkis launched Ultragenyx Pharmaceutical in Novato and the EveryLife Foundation for Rare Diseases, lobbying for legislative changes to make it easier to develop rare disease drugs.
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.